Page 17 - Read Online

addition, apart from what is being delivered, it is essential that understand more about tumor biology, it will be easier to identify
it is delivered correctly, which means that the interventional those patients that will benefit the most from this treatment.
radiologist has to aim for lobar or sublobar branches of the
hepatic artery and not simply deliver the therapeutic regimen REFERENCES
to the main hepatic artery, as this will include the liver as a
whole and create more side-effects by affecting an already- 1. Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma
fragile remaining healthy liver. Significant progress and epidemiology. Best Pract Res Clin Gastroenterol 2014;28:753-70.
improvement in the results have been seen in the last decade 2. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K,
Takashima S. Hepatic artery embolization in 120 patients with
or so when microcatheters have been increasingly used, thus unresectable hepatoma. Radiology 1983;148:397-401.
providing more accuracy in the delivery. Furthermore, although 3. Dash A, Knapp FF, Pillai MR. Targeted radionuclide therapy - an
the preferred treatment in patients with cirrhosis and tumors overview. Curr Radiopharm 2013;6:152-80.
within the Milan criteria is liver transplantation, TACE has been 4. Boily G, Villeneuve JP, Lacoursière L, Chaudhury P, Couture F,
Ouellet JF, Lapointe R, Goulet S, Gervais N; Comité de L’évolution
shown to have either a neoadjuvant role of sorts by providing a des Pratiques en Oncologie. Transarterial embolization therapies for
downstaging or bridging therapy or an adjuvant treatment role the treatment of hepatocellular carcinoma: CEPO review and clinical
(alone or with sorafenib) in the case of HCC recurrence, which recommendations. HPB (Oxford) 2015;17:52-65.
is the main problem after liver transplantation. There is also a 5. Gamblin TC, Geller DA. Downstaging hepatocellular carcinoma prior
[5]
to liver transplantation. Liver Transpl 2005;11:1466-8.
significant ongoing discussion regarding the contraindications 6. Xue TC, Xie XY, Zhang L, Yin X, Zhang BH, Ren ZG. Transarterial
in the use of TACE, as these are also evolving with the once chemoembolization for hepatocellular carcinoma with portal vein tumor
absolute contraindication of portal vein thrombosis, now thrombus: a meta-analysis. BMC Gastroenterol 2013;13:60.
being a relative one with proper patient selection. Finally, 7. Sato Y, Watanabe H, Sone M, Onaya H, Sakamoto N, Osuga K,
[6]
Takahashi M, Arai Y; Japan Interventional Radiology in Oncology
when discussing a treatment, it is important to have ways of Study Group-JIVROSG. Tumor response evaluation criteria for HCC
assessing its efficacy, other than patient overall survival. In (hepatocellular carcinoma) treated using TACE (transcatheter arterial
the case of TACE, this has led to the use of the assessment chemoembolization): RECIST (response evaluation criteria in solid
of re-treatment with TACE prognostic system in the case of tumors) version 1.1 and mRECIST (modifi ed RECIST): JIVROSG-0602.
Ups J Med Sci 2013;118:16-22.
multiple treatments and to the modified Response Evaluation
Criteria in Solid Tumors criteria. [7]
How to cite this article: Tsoulfas G. The evolving role of transarterial
chemoembolization in the management of hepatocellular carcinoma.
Although the above may mean that there still several unresolved Hepatoma Res 2015;1:9-10.
issues regarding the use of TACE in the treatment of HCC, the key
fact remains that the technique continues to evolve and as we Source of Support: Nil. Confl ict of Interest: None declared.

10 Hepatoma Research | Volume 1 | Issue 1 | April 15, 2015